Add to ORKGGAR-936 is a new semisynthetic glycylcycline with a broad antibacterial spectrum, including tetracycline-resistant strains. The in vitro activities of GAR-936, minocycline, doxycycline, tetracycline, moxifloxacin, penicillin G, and erythromycin were determined by agar dilution methods against 268 aerobic and 14
GV129606 is a new parenteral trinem antibiotic belonging to the b-lactam class. It combines broad-sp...
Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans. It...
that of other agents with anti-anaerobe activity against clinical anaerobic isolates, with emphasis ...
The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycyl...
tetracycline, cephalothin, penicillin G, and amoxicillin-clavulanic acid against 173 recent clinical...
N,N-Dimethylglycylamido (DMG) derivatives of minocycline and 6-demethyl-6-deoxytetracycline are new ...
aerobic and anaerobic bite wound isolates. other oral antimicrobial agents against 194 Bay y 3118, l...
In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant ente...
anaerobic bite wound isolates. ciprofloxacin against 387 aerobic and levofloxacin, ofloxacin, sparfl...
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peri...
minocycline and 6-demethyl-6-deoxytetracycline, respectively. In vitro activities of these two antim...
The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluat...
The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcu...
The likelihood of bacterial resistance now prevents the use of oxytetracydine in the empirical thera...
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and s...
GV129606 is a new parenteral trinem antibiotic belonging to the b-lactam class. It combines broad-sp...
Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans. It...
that of other agents with anti-anaerobe activity against clinical anaerobic isolates, with emphasis ...
The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycyl...
tetracycline, cephalothin, penicillin G, and amoxicillin-clavulanic acid against 173 recent clinical...
N,N-Dimethylglycylamido (DMG) derivatives of minocycline and 6-demethyl-6-deoxytetracycline are new ...
aerobic and anaerobic bite wound isolates. other oral antimicrobial agents against 194 Bay y 3118, l...
In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant ente...
anaerobic bite wound isolates. ciprofloxacin against 387 aerobic and levofloxacin, ofloxacin, sparfl...
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peri...
minocycline and 6-demethyl-6-deoxytetracycline, respectively. In vitro activities of these two antim...
The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluat...
The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcu...
The likelihood of bacterial resistance now prevents the use of oxytetracydine in the empirical thera...
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and s...
GV129606 is a new parenteral trinem antibiotic belonging to the b-lactam class. It combines broad-sp...
Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans. It...
that of other agents with anti-anaerobe activity against clinical anaerobic isolates, with emphasis ...